Scholar Rock Updates on FDA Warning and Apitegromab Launch Plans
I'm PortAI, I can summarize articles.
Scholar Rock Holding Corp provided updates on FDA interactions and product launch plans. FDA issued a warning letter to Catalent Indiana on facility issues, which are being resolved. Scholar Rock plans to resubmit its biologics license application in 2026. U.S. launch of apitegromab for spinal muscular atrophy expected post-approval.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments